avobenzone
Trade name: shade uvaguard
Small moleculeapproved
Approved
Dec 7, 1992
Avobenzone is an oil soluble ingredient used in sunscreen products to absorb the full spectrum of UVA rays. It helps prevent sunburn. Avobenzone works by absorbing the rays and converting them to energy that is less damaging to the skin. — NCATS
Clinical trial activity
9 trials · 7 clinical orgs · 4 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
3
Phase 4
1
Earliest trial started May 1, 2006 (NCT00326274)
Timeline
Indications
Approved for
Mechanism of action
- Unspecified targetUltraviolet filter
ultraviolet filter
Combination products
anthelios
with titanium, octocrylene, ecamsule
anthelios sx
with octocrylene, ecamsule
Also known as capital soleil
shade uvaguar
with oxybenzone, octinoxate
Approval history
- approvedDec 7, 1992
Chemistry & pharmacology
Loading structure…
SMILES
COC1=CC=C(C=C1)C(=O)CC(=O)C2=CC=C(C=C2)C(C)(C)C- Mol. weight
- 310.3869 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Topical
- Availability
- Over the Counter
Oral
No
Parenteral
No
Topical
Yes
Sources
- WikipediaAvobenzone ↗
- NCATSG63QQF2NOX ↗
- ChEMBLCHEMBL1200522 ↗
Also known as
- 4-tert-butyl-4'-methoxydibenzoylmethane
- avobenzone
- avobenzone
- avobenzone
- avobenzone
- avobenzone
- avobenzone
- avobenzone
- avobenzone
- avobenzone
- butylmethoxydibenzoylmethane
- butyl methoxydibenzoylmethane
- butyl methoxydibenzoylmethane
- butyl methoxydibenzoylmethane
- butyl methoxydibenzoylmethane
- butyl-methoxy-dibenzoylmethane
- parsol 1789
- parsol 1789
- parsol 1789
- parsol 1789
- parsol-1789
- photoplex
- shade uvaguard
- shade uvaguard
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05865431 | N/A | Mar 17, 2017 | University of California, Davis |
| NCT03012347 | N/A | Jan 1, 2017 | Bayer |
| NCT02877511 | N/A | Aug 1, 2016 | Bayer |
| NCT01695356 | Phase 4 | Sep 1, 2012 | Universidad Autonoma de San Luis Potosi |
| NCT01001975 | Phase 3 | Jul 1, 2009 | Bayer |
| NCT00530387 | N/A | Jul 1, 2008 | University of Dundee |
| NCT00701740 | Phase 2 | Jul 1, 2007 | University of Sao Paulo |
| NCT00368563 | Phase 2/Phase 3 (Phase 3) | Aug 1, 2006 | Hill Top Research, L'Oreal |
| NCT00326274 | Phase 3 | May 1, 2006 | L'Oreal |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bayer | For profit | 3 | 3 | 2 | 2009 |
| L'Oreal | For profit | 2 | 2 | 1 | 2006 |
| Hill Top Research | For profit | 1 | 0 | 1 | 2006 |
| Universidad Autonoma de San Luis Potosi | Academic/Hospital | 1 | 1 | 1 | 2012 |
| University of California, Davis | Academic/Hospital | 1 | 1 | 1 | 2017 |
| University of Dundee | Academic/Hospital | 1 | 1 | 1 | 2008 |
| University of Sao Paulo | Academic/Hospital | 1 | 1 | 1 | 2007 |
7 organizations
Page 1 / 1
Marketing (4)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Bayer | For profit | NDA2 | Dec 7, 1992 |
| L'Oreal | For profit | NDA2 | Jul 21, 2006 |
| Sanofi-Aventis | For profit | NDA2 | Jul 21, 2006 |
| Schering-Plough | For profit | NDA | — |